Maarten Limper

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4721972/publications.pdf

Version: 2024-02-01

1162367 940134 21 328 8 16 citations h-index g-index papers 22 22 22 435 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	1.1	97
2	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews, 2018, 17, 1153-1168.	2.5	62
3	Frequencies and clinical associations of myositis-related antibodies in The Netherlands: A one-year survey of all Dutch patients. Journal of Translational Autoimmunity, 2019, 2, 100013.	2.0	34
4	Pregnancy outcome predictors in antiphospholipid syndrome: A systematic review and meta-analysis. Autoimmunity Reviews, 2021, 20, 102901.	2.5	30
5	The immunologic etiology of psychiatric manifestations in systemic lupus erythematosus: A narrative review on the role of the blood brain barrier, antibodies, cytokines and chemokines. Autoimmunity Reviews, 2020, 19, 102592.	2.5	26
6	An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus. Rheumatology, 2018, 57, 1707-1720.	0.9	25
7	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. Clinical and Experimental Rheumatology, 2022, 40, 3-11.	0.4	12
8	Text Mining of Electronic Health Records Can Accurately Identify and Characterize Patients With Systemic Lupus Erythematosus. ACR Open Rheumatology, 2021, 3, 65-71.	0.9	10
9	Immunomodulation Through Low-Dose Radiation for Severe COVID-19: Lessons From the Past and New Developments. Dose-Response, 2020, 18, 155932582095680.	0.7	8
10	Clone-directed therapy for proliferative glomerulonephritis with monoclonal immunoglobulin depositions: is it always necessary?. Journal of Nephrology, 2020, 33, 611-617.	0.9	8
11	Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation. Clinical and Experimental Rheumatology, 2022, 40, 93-102.	0.4	5
12	Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients. Rheumatology, 2022, 61, 4087-4096.	0.9	4
13	Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies. Lupus Science and Medicine, 2021, 8, e000531.	1.1	3
14	Diagnosis and treatment of patients with antiphospholipid syndrome: a mixed-method evaluation of care in The Netherlands. Rheumatology Advances in Practice, 2020, 4, rkaa021.	0.3	2
15	Gamna-Gandy nodules of the spleen and asplenism in SLE: a novel association?. BMJ Case Reports, 2017, 2017, bcr-2017-220566.	0.2	1
16	Microarray analysis of autoantibodies can identify future Systemic Lupus Erythematosus patients. Human Immunology, 2022, 83, 509-514.	1.2	1
17	FRIO607â€IDENTIFICATION OF UNMET NEEDS RELATED TO RARE AND COMPLEX CONNECTIVE TISSUE AND MUSCULOSKELETAL DISEASES (RCTDS) ACROSS EU: THE EXPERIENCE OF THE ERN RECONNET. , 2019, , .		0
18	P5â€Recognizing the disease, treating the patient: a mixed-method evaluation of care for the antiphospholipid syndrome (APS) in the Netherlands. , 2020, , .		0

#	Article	IF	CITATIONS
19	P14â€Microarray analysis identifies Anti-CpG antibodies to be strongly associated with SLE and lupus nephritis. , 2020, , .		O
20	On the use of intravenous immunoglobulins for the treatment of the antiphospholipid syndrome – A systematic review and meta-analysis. Autoimmunity Reviews, 2021, 20, 102828.	2.5	0
21	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET Clinical and Experimental Rheumatology, 2022, , .	0.4	0